Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors

The PD-1/PD-L1 pathway is a key immune checkpoint that regulates T cell activation. There is strong rationale to develop PD-1 agonists as therapeutics against autoimmunity, but progress in this area has been limited. Here, we generated T cell receptor (TCR) targeting, PD-1 agonist bispecifics called...

Descripción completa

Detalles Bibliográficos
Autores principales: Curnock, Adam P., Bossi, Giovanna, Kumaran, Jyothi, Bawden, Lindsay J., Figueiredo, Rita, Tawar, Rajeevkumar, Wiseman, Katherine, Henderson, Emma, Hoong, Sec Julie, Gonzalez, Veronica, Ghadbane, Hemza, Knight, David E.O., O’Dwyer, Ronan, Overton, David X., Lucato, Christina M., Smith, Nicola M.G., Reis, Carlos R., Page, Keith, Whaley, Lorraine M., McCully, Michelle L., Hearty, Stephen, Mahon, Tara M., Weber, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564903/
https://www.ncbi.nlm.nih.gov/pubmed/34491911
http://dx.doi.org/10.1172/jci.insight.152468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564903/
https://www.ncbi.nlm.nih.gov/pubmed/34491911
http://dx.doi.org/10.1172/jci.insight.152468

Ejemplares similares